Relay Therapeutics, Inc. 4

Donald A. Bergstrom (President, R&D of Relay Therapeutics, Inc.) sold 8,660 shares of common stock at about $18.71 per share under a Rule 10b5-1 plan.

On July 6, 2026, Donald A. Bergstrom, President, R&D of Relay Therapeutics, Inc., sold 8,660 shares of the company’s common stock at a weighted average price of approximately $18.71 per share under a pre-arranged Rule 10b5-1 trading plan, for total proceeds of about $162,000. Following this planned sale, which was executed in multiple trades within a price range of $18.45 to $19.36, Bergstrom’s direct ownership stands at 409,897 shares, including 15,037 shares underlying restricted stock units, indicating he continues to hold a substantial equity position in the company.

Filing Facts

CIK

1812364

Ticker

RLAY

Form

4

Source Type

fda

Accession

0001193125-26-298688

Alert Tier

5